Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. reports developments across its orthopedic and spine medical technology portfolio. The company provides spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH Navigation System, for complex musculoskeletal conditions.
Recurring OFIX news includes quarterly results, guidance, product launches and commercial execution in Spine and Orthopedics. Company updates also cover pediatric limb reconstruction offerings such as FITBONE, planning software such as OrthoNext, the TRUELOK Elevate system, spine leadership realignment, distributor transitions, biologics activity and the discontinued M6 artificial disc product lines.
Orthofix Medical Inc. (NASDAQ:OFIX) announced it will release its financial results for the first quarter of 2021 on April 30, 2021, before market opening. A conference call led by CEO Jon Serbousek and CFO Doug Rice will occur at 8:30 a.m. ET the same day. Interested parties can join via phone or access the webcast on the company's investor relations site. Orthofix focuses on innovative medical devices for spine and extremities, distributing products in over 70 countries.
Orthofix Medical (NASDAQ: OFIX) has received FDA 510(k) clearance and successfully implanted its FORZA™ Ti TLIF Spacer System, designed for Transforaminal Lumbar Interbody Fusion. This 3D-printed titanium implant incorporates Nanovate™ Technology to promote bone growth during spinal fusion. Key features include optimized porosity and a large graft window. Orthofix aims to address current surgeon needs and enhance patient outcomes with this innovative system, building on the recent launch of its cervical interbody product. The product rollout will target specific commercial channels.
Orthofix Medical (NASDAQ: OFIX) announces leadership changes as Chairman Ron Matricaria and director Maria Sainz will not seek re-election at the 2021 Annual Meeting. Catherine Burzik has been nominated as the new Chair of the Board. Burzik brings over 30 years of experience in the medical device sector, having held executive roles at Kinetic Concepts, Johnson & Johnson, and Eastman Kodak. The Board's size will decrease from nine to eight members. CEO Jon Serbousek welcomed Burzik's experience to aid in Orthofix's continued growth and commitment to patient care.
Orthofix Medical Inc (NASDAQ:OFIX) has received FDA 510(k) clearance for its innovative 3D-printed CONSTRUX Mini Ti Spacer System, aimed at enhancing anterior cervical discectomy and fusion (ACDF) procedures. The first patient implant has been successfully completed. This titanium spacer incorporates Nanovate Technology, promoting bone growth and fusion. Compared to solid PEEK devices, its 3D-printed structure significantly enhances osteogenic growth factors. Orthofix aims to expand its cervical spine portfolio, with a commitment to improving patient outcomes.
Summary not available.
Orthofix Medical reported its Q4 and FY 2020 financial results, showing Q4 net sales of $117.6 million, a decline of 3.2% year-over-year. The company recorded a net loss of $9.4 million, or $(0.48) per share. Adjusted EPS was $0.44. For FY 2020, net sales reached $406.6 million with EPS of $0.13. The company highlighted operational resilience amidst COVID-19 disruptions and noted an expanded FDA clearance for the FITBONE® system. Guidance for 2021 anticipates net sales between $445 million and $460 million, reflecting a year-over-year increase.
Orthofix Medical Inc. (NASDAQ:OFIX) announced that its President and CEO, Jon Serbousek, and CFO, Doug Rice, will participate in a fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference on February 19, 2021, at 9:30 a.m. ET. This virtual event will include one-on-one meetings before and after the chat. A live audio webcast will be available on Orthofix's website for those interested in following the discussion.
Orthofix, based in Lewisville, Texas, focuses on innovative medical device solutions for spine and extremities.
Orthofix Medical Inc. (NASDAQ:OFIX) has announced its plans to report financial results for the fourth quarter and full year 2020 on February 26, 2021, before market open. CEO Jon Serbousek and CFO Doug Rice will discuss the results during a conference call at 8:30 a.m. ET that day. Interested participants can join the call by dialing specific numbers or access a webcast through the company's investor relations website. Orthofix is focused on innovative medical device solutions, distributing products in over 70 countries.
Orthofix Medical Inc. (NASDAQ:OFIX) announced the full market launch of its FITBONE® intramedullary lengthening system in the U.S. and Europe for femur and tibia deformity corrections. The system, which is fully implantable, has been used in over 3,500 cases across 15 countries. It gained U.S. FDA 510(k) clearance and CE Mark approval in Europe. This expansion aims to improve treatment options for surgeons and patients. Orthofix offers a comprehensive portfolio of fixation solutions, enhancing its market presence in orthopedic care.
Orthofix Medical (NASDAQ:OFIX) published two-year data from its U.S. IDE study of the M6-C™ artificial cervical disc, demonstrating that the device is safe and effective for treating cervical disc degeneration. The study showed an overall success rate of 86.8% for M6-C patients compared to 79.3% for anterior cervical discectomy and fusion (ACDF) patients. At 24 months, M6-C patients reported significant reductions in pain and medication use, with a 91.2% improvement in neck pain. Orthofix aims to enhance patient outcomes with this innovative technology, emphasizing its commitment to quality-driven medical solutions.